Objective. In vestibular schwannoma treatment, the choice among treatment modalities is controversial. The first aim of this study was to examine the quality of life of patients with vestibular schwannoma having undergone observation, radiation therapy, or microsurgical resection. The second aim was to examine the relationship between perceived symptoms and quality of life. Last, the association between quality of life and time since treatment was studied.
A proportion of vestibular schwannomas (VSs) exhibit rapid growth; yet, the majority of tumors are slow growing, and a significant proportion show no detectable growth at all over a period of several years. [1] [2] [3] Observation, also known as wait-and-scan or watchful waiting, is therefore considered a safe treatment for patients with small, slow-growing tumors and a moderate display of symptoms. Other factors might be taken into consideration, including age, concurrent medical risk, hearing status, and patient preference. 2, 4 However, in case of progressive growth or increasing symptoms, conversion to active treatment may be necessary.
The choice among treatment modalities is controversial, and consensus is lacking, particularly for tumors \30 mm in diameter. [5] [6] [7] [8] Over the years, studies have focused on traditional outcome measures, such as tumor control, facial nerve function, and hearing. Current studies comparing treatment methods are based on level 2 evidence at best, as no randomized trials on the subject have been successfully conducted. 9, 10 Prospectively conducted studies comparing radiation therapy (RT) and microsurgical resection (MS) have demonstrated no major differences between these treatment modalities. Some studies have reported better shortterm hearing and facial nerve outcomes for patients undergoing RT 6, 9, 11 ; however, it may take up to 10 years for the effects of RT on hearing to reach its full impact. 12, 13 Furthermore, to what extent these functional outcomes affect the patient's quality of life (QOL) is unclear. [14] [15] [16] [17] Because VS is a benign condition, it could be argued that as survival is not the issue, QOL becomes all the more important. This is reflected in QOL having emerged as an increasingly important factor in the literature on VS treatment. Several study groups have evaluated the effect of the various treatments on patients' QOL, many using well-known generic assessment instruments, such as the Short Form236 Questionnaire (SF-36) and the Glasgow Benefit Inventory. 9, 16, [18] [19] [20] [21] Nevertheless, the use of disease-specific measures is essential for measuring small, clinically important changes caused by the disease and its different treatments. 22 Until now, five study groups have used the disease-specific Penn Acoustic Neuroma Quality of Life (PANQOL) scale, developed by Shaffer et al. [23] [24] [25] [26] [27] [28] Three of these groups evaluated the QOL of patients with VS having undergone observation, RT, or MS but mostly with relatively small samples. 25, 26, 28 The first aim of this study was to examine the QOL of patients with VS having undergone observation, RT, or MS, according to tumor size. The second aim was to examine the relationship between perceived symptoms and QOL. Last, the association between QOL and time since treatment was studied.
Materials and Methods Participants
Participants were cross-sectionally recruited through a tertiary referral center in the Netherlands. They were consecutively drawn from a database containing all patients at this center with VS. Patients included in the study had been diagnosed with unilateral VS and started treatment consisting of observation, RT, or MS in the period from January 2004 until January 2014. Exclusion criteria were defined as patients with skull base pathology other than VS, patients with neurofibromatosis type 2, those who had received multiple active treatments, or those who had undergone active treatment \1 month prior to receiving the survey. Patients not proficient in the Dutch language or otherwise incapable of completing a written questionnaire were also excluded.
Materials
PANQOL Scale: Dutch Version. The 26-item PANQOL scale is the only disease-specific QOL instrument for VS and was translated and validated for the Dutch population by the current study group in 2013. 24 Its 7 domains comprise symptoms associated with VS: balance, hearing, anxiety, energy, pain, face, and general well-being. Questions are rated on a scale from 1 (strongly disagree) to 5 (strongly agree). Internal consistency of the domains (Cronbach's alpha) was calculated as 0.94, 0.75, 0.88, 0.91, 0.65, and 0.31, respectively (with the exception of pain, as it contains only 1 item). 24 A total instrument score is calculated as the unweighted average of the domain scores and reported on a scale from 0 to 100 (worst to best QOL).
Sociodemographics, Symptoms, and Tumor Characteristics. Participants also answered questions on sociodemographic characteristics comprising educational level, marital status, living situation, and employment, as well as questions regarding the manifestation of symptoms associated with VS. Patients were asked to rate their hearing status, tinnitus, balance, vertigo, facial pain, and facial weakness on a scale from 1 (best imaginable) to 5 (worst; see Appendix A in the online version of the article). A composite symptom score was calculated as the unweighted average of self-reported symptom scores.
Through retrospective chart review, additional information was obtained regarding age, sex, date of diagnosis and treatment, tumor size at diagnosis, symptoms at diagnosis (reported at first consultation), and whether there was a cystic aspect to the lesion. Tumor size was measured and categorized according to the international Kanzaki consensus guidelines 29 as the largest cerebellopontine angle diameter on magnetic resonance imaging, with small comprising intrameatal and grade 1 tumors (0-10 mm), medium consisting of grade 2 tumors (11-20 mm), and large including grades 3 through 5 (.21 mm).
Procedure. Permission for the study was granted by the Medical Ethics Committee of the Leiden University Medical Center. Patients were mailed the questionnaires and asked to complete and return them in a postage-paid envelope. Patients were categorized according to final treatment. Treatment date, used to determine time since treatment, consisted of the date of diagnosis for patients in the observation group. Patients were categorized in the RT or MS treatment group regardless of surgical approach or type of RT.
Statistical Analysis. Statistical analysis was performed with SPSS 21.0. Results were considered statistically significant at P .05. Treatment groups were compared regarding sociodemographic and tumor characteristics as well as symptoms at diagnosis with unpaired t testing and analysis of variance.
Based on the data, literature, and expert opinion, sex, educational level, presence of a cystic aspect to the lesion, and symptoms at diagnosis were identified as potential confounders. The probability of treatment assignment dependent on these observed confounders, the propensity score, was calculated and used in a multiple linear regression analysis to control for confounding in the comparison of the PANQOL scores for the different treatment arms. 30 Results were stratified per tumor size according to the Kanzaki guidelines. To detect possible cutoff levels for tumor size above which treatment had no further effect on QOL, a sensitivity analysis was performed stepwise, for increasing levels of tumor size.
The relationship between self-reported symptoms and QOL was examined with Pearson's correlation coefficient. This method was also used to detect a potential linear relationship between QOL and time since treatment.
Results

Baseline Population Data
Of 1228 patients initially matching the inclusion criteria, 14 were excluded because they were living abroad and 6 because of incomplete or missing contact information. Out of 1208 potential participants, 919 returned the questionnaire (response rate, 76%). A comparison of responders and nonresponders revealed no significant differences in age, tumor size, symptoms at diagnosis, and time since diagnosis. There were, however, more males among responders than nonresponders (52.1% vs 45.7%, P = .049) and more patients who had undergone surgery (31.5% vs 23.7%, P = .031). Out of all returned questionnaires, 112 were partially incomplete, rendering their total instrument score unattainable. These patients were excluded from analysis. Of the final 807 participants, 436 (54%) were male. With regard to treatment strategy, 469 (58%) patients had undergone observation; 81 (10%), RT; and 257 (32%), MS. Table 1 presents sociodemographics as well as tumor characteristics and the presence of symptoms at diagnosis for each treatment group.
Tumor size at diagnosis differed significantly among treatment groups, with the largest average size in the MS group. Treatment arms also differed significantly regarding educational level, with more than half of the RT group having completed tertiary education, as opposed to roughly one-third of participants in the observation and MS groups. Mean time since treatment was lowest in the RT group. Regarding symptoms at diagnosis, tinnitus, balance, and vertigo were least affected in the observation group. The percentage of patients affected by severe hearing loss (.50 dB) did not differ at diagnosis, and facial nerve function was least often impaired in the RT group at diagnosis.
Treatment and QOL according to Tumor Size
Total PANQOL scores per treatment group, stratified according to tumor size, are displayed in Figure 1 . After correction for potential confounders, a statistically significant difference in total PANQOL score was found for patients with small tumors (P = . Figure 2 .
Self-reported Symptoms
The relationship between self-reported symptoms and QOL was investigated via Pearson's correlation coefficient. All 6 symptoms were negatively correlated with the total PANQOL score. Balance problems and vertigo proved to be most strongly correlated (r = 20.62 and 20.55, respectively; P .001); however, correlations with hearing loss (r = 20.32), tinnitus (r = 20.38), facial nerve involvement (r = 20.30), and trigeminal nerve involvement (r = 20.46) were also significant (P .001), leading to a correlation of overall symptoms (as measured by composite symptom score) and QOL of20.73 (P .001).
Time since Treatment
To evaluate any trends in total QOL during the time after treatment, the number of years since treatment was plotted against the PANQOL score for the treatment groups as well as for all groups combined ( Figure 3) . No clear pattern or significant differences among treatment groups emerged. Pearson's correlation coefficient showed no significant linear relationship between time and QOL.
Discussion
Adequately measuring treatment outcome for patients with VS has proven to be challenging. Unfortunately, randomization does not appear to be a viable option for patients with this condition, and treatment outcomes are difficult to compare due to inconsistently classified variables, such as tumor size and hearing loss. Comparable treatment results on traditional end points, such as tumor control and hearing, have put the focus on patient-reported outcomes in general and QOL in particular.
The PANQOL scale has been used by 2 other study groups to compare long-term QOL for the 3 treatment modalities. A high Cronbach's alpha was found for all dimensions, except for general health (0.31). This is explained by the fact that there are only 2 questions about general health in this questionnaire. Robinett et al subdivided their study population into groups based on years of follow-up and found a statistically significant difference for the interval from 1 to 5 years, where the RT group had higher QOL scores. 25 In the study conducted by Carlson et al, the RT and observation groups had higher QOL scores than the MS group. 28 Our study has not been able to reproduce these results and instead found a significantly better QOL for patients with small tumors (10 mm) undergoing observation. The current study is the first to stratify results according to tumor size and correct for potential confounders. Nonetheless, differences in QOL were relatively small in all 3 studies and, although statistically significant, may not be clinically relevant, as Carlson et al demonstrated in their recent study about the minimal clinically important difference (MCID) in VS QOL assessment. 31 However, we feel that a difference of 5.91 points on a 100-point scale cannot instantly be discarded as clinically irrelevant, as MCIDs are known to vary by study population and clinical context. Furthermore, the MCIDs demonstrated by Carlson et al for the total PANQOL score (9 for distribution-and 11 for anchor-based estimates) are included in the confidence interval of the difference found in the current study. A cautionary remark with regard to stratification is that we used tumor size at diagnosis, even though progression of the tumor could have been a reason to convert to active intervention.
When domain scores of the PANQOL were examined, outperformance of the observation group, as compared with the RT and MS groups, among patients with small tumors was evident for the domains of balance and energy. It could therefore be hypothesized that these domains are the areas most affected by active treatment. However, we cannot exclude the possibility that the patients in the RT and MS groups were more affected in these domains before starting active treatment. The only significant difference between the RT and MS groups was demonstrated for the face subdomain, which is in accordance with scientific literature, describing 2% to 19% of facial neuropathy in patients subjected to RT, as compared with 14% to 29% in patients undergoing MS. 5 A last noteworthy outcome in the comparison of treatment groups was the large amount of higher-educated participants in the RT group, something that has not been described in VS literature before. Previously identified predictors for treatment choice were discipline of the attending physician, tumor size, and age. 32 Research in patients with hematologic malignancy has demonstrated lower educational level to be associated with a higher need for psychosocial information. That study also indicated that higher satisfaction with provided information was related to a more favorable QOL. 33 It might therefore be beneficial to further explore the relationship between educational level, information satisfaction, and QOL in patients with VS.
In this study, a strong correlation was found between PANQOL scores and self-reported symptoms, implying that the degree of perceived complaints is a strong indication of QOL. Significant negative correlations of varying degree were found for all reported symptoms, with balance and vertigo having the largest impact. Because of a high degree of correlation between these 2 symptoms (r = 0.65, P \ .001), it was not possible to adequately differentiate between them. Other studies, however, have also linked vestibular symptoms to a deterioration in QOL. There is little evidence of other symptoms associated with a change in health status as measured by the SF-36. [14] [15] [16] [17] 34 This might be attributed to the use of a generic tool, as it does not address bodily senses such as hearing.
No correlation was found between QOL and time since treatment. This is largely in line with the most recent prospective study of QOL in VS by Di Maio and Akagami, in which QOL remained unchanged for the observation and RT groups throughout a mean follow-up of 31.8 months. The MS group in that study reported a significant improvement only at 24 months, after which the total score returned to baseline. The authors attributed this finding to MS patients reporting less frequently that VS affected their QOL, possibly due to a sense of definitive treatment and therefore less psychological burden. 20 Given the uncertainty and ambivalence surrounding the evidence on traditional outcome measures, the aim of this study was to compare the association of different treatment modalities for VS with long-term QOL. The study was conducted with a cross-sectional design, and it has the largest number of respondents when compared with similar studies using the PANQOL scale. 25, 26, 28 Limitations of the study include possible introduction of confounding factors (particularly confounding by indication) due to the observational design, as well as the nonprospective nature of the study, which prevents the inference of causality. To reduce confounding, we adjusted the total PANQOL score for potential confounders by applying stratification and a linear regression model. 35 Another method is to prevent confounding in the design phase of the study (eg, by restriction or matching); however, this method was deemed inappropriate because it would have severely limited the size of our treatment groups. With regard to confounding by indication, this can be completely prevented only by randomization, which appears to be infeasible for this particular condition. 9 
Conclusion
The findings of the current study indicate that patients with small tumors (10 mm) have a better QOL when undergoing observation when compared with patients who have undergone active treatment. It has been argued that based on clinical reasoning alone, the decision not to initiate active therapy is well defended for patients with small tumors. 2, 4, 36, 37 Adding the outcome of the current study to the existing body of evidence only strengthens this conception, as active treatment can be justified only when its outcome is more preferable than the natural progression of the disease. However, current studies examining diseasespecific QOL are all cross-sectional in design; results vary; and the reported differences are small and potentially clinically insignificant. To establish the superiority of one treatment over another with regard to QOL, more prospectively designed research is needed. The results of the current study can, however, be of value in the communication with patients about their expectations regarding QOL after treatment and the effect that specific symptoms can have on their QOL.
